Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12060386 Compositions and methods for treating CNS disorders

Patent 12060386 was granted and assigned to SAGE Therapeutics on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

SAGE Therapeutics

0

Current Assignee

SAGE Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Albert Jean Robichaud0

Francesco G. Salituro0

Date of Patent

August 13, 2024

0

Patent Application Number

183055290

Date Filed

April 24, 2023

0

Patent Citations

US Patent 10023606 19-nor neuroactive steroids and methods of use thereof

0

US Patent 9365611 19-NOR neuroactive steroids and methods of use thereof

0

US Patent 9512165 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof

0

US Patent 9630986 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

0

US Patent 9676812 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

0

US Patent 9725481 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof

0

US Patent 11396525 C17, C20, and C21 substituted neuroactive steroids and their methods of use

0

US Patent 11426417 Neuroactive steroid formulations and methods of treating CNS disorders

0

...

Patent Primary Examiner

Timothy R Rozof

0

CPC Code

0

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12060386 Compositions and methods for treating CNS disorders

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool